| Literature DB >> 31271738 |
Sofia Romano1, Nuno Fonseca2, Sérgio Simões3, João Gonçalves4, João Nuno Moreira5.
Abstract
Cancer is currently the second leading cause of death worldwide and current therapeutic approaches remain ineffective in several cases. Therefore, there is a need to develop more efficacious therapeutic agents, especially for subtypes of cancer lacking targeted therapies. Limited drug penetration into tumors impairs the efficacy of therapies targeting cancer cells. One of the strategies to overcome this problem is targeting the more accessible tumor vasculature via molecules such as nucleolin, which is expressed at the surface of cancer and angiogenic endothelial cells, thus enabling a dual cellular targeting strategy. In this review, we present and discuss nucleolin-based targeting strategies that have been developed for cancer therapy, with a special focus on recent antibody-based approaches.Entities:
Mesh：
Substances：
Year: 2019 PMID： 31271738 DOI： 10.1016/j.drudis.2019.06.018
Source DB: PubMed Journal: Drug Discov Today ISSN： 1359-6446 Impact factor: 7.851